SI2691112T1 - Stabilne formulacije protiteles za humani programiran smrtni receptor pd-1 in sorodna zdravljenja - Google Patents
Stabilne formulacije protiteles za humani programiran smrtni receptor pd-1 in sorodna zdravljenja Download PDFInfo
- Publication number
- SI2691112T1 SI2691112T1 SI201231319T SI201231319T SI2691112T1 SI 2691112 T1 SI2691112 T1 SI 2691112T1 SI 201231319 T SI201231319 T SI 201231319T SI 201231319 T SI201231319 T SI 201231319T SI 2691112 T1 SI2691112 T1 SI 2691112T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antibody
- human
- pharmaceutical formulation
- liquid pharmaceutical
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
- STABILNE FORMULACIJE PROTITELES ZA HUMANI PROGRAMIRAN SMRTNI RECEPTOR PD-1 IN SORODNA ZDRAVLJENJA PATENTNI ZAHTEVKI1. Stabilna liofilizirana formulacija anti-humanega PD-1 protitelesa, izdelana z liofilizacijo vodne raztopine, ki obsega: a) 25-100 mg/ml anti-humanega PD-1 protitelesa; b) 70 mg/ml saharoze; c) 0,2 mg/ml polisorbata 80; in d) 10 mM histidinski pufer pri pH 5,0 - pH 6,0, in kjer protitelo obsega: lahko verigo, ki obsega aminokislinske ostanke 20 do 237 SEQ ID NO: 36 in težko verigo, ki obsega amino kislinske ostanke 20 do 466 SEQ ID NO: 31.
- 2. Stabilna tekoča farmacevtska formulacija anti-humanega PD-1 protitelesa, ki obsega: a) 25-100 mg/ml anti-humanega PD-1 protitelesa; b) 70 mg/ml saharoze; c) 0,2 mg/ml polisorbata 80; in d) 10 mM histidinski pufer pri pH 5,0-6,0, kjer protitelo obsega: lahko verigo, ki obsega aminokislinske ostanke 20 do 237 SEQ ID NO: 36 in težko verigo, ki obsega amino kislinske ostanke 20 do 466 SEQ ID NO: 31.
- 3. Formulacija po zahtevku 1 ali 2, kjer je anti-humano PD-1 protitelo prisotno pri 25 mg/mL v vodni raztopini.
- 4. Formulacija po zahtevku 1,2 ali 3, kjer ima vodna raztopina pH 5,5.
- 5. Formulacija po katerem koli od predhodnih zahtevkov, kjer je protitelo h409A11.
- 6. Stabilna liofilizirana farmacevtska formulacija po zahtevku 1, kjer vodna raztopina obsega 25,0 mg/ml anti-humanega PD-1 protitelesa, 1,55 mg/ml histidina, 0,2 mg/ml polisorbata 80, 70 mg/ml saharoze in ima pH od 5,5; kjer je anti-humano PD-1 protitelo h409A11.
- 7. Tekoča farmacevtska formulacija po katerem koli od zahtevkov 2 do 6, za uporabo pri metodi zdravljenja s terapijo.
- 8. Tekoča farmacevtska formulacija za uporabo po zahtevku 7, kjer je terapija zdravljenje raka.
- 9. Tekoča farmacevtska formulacija za uporabo po zahtevku 8, kjer je doza izbrana izmed 1,0, 3,0 in 10 mg/kg ki se dajejo v intervalih 14 dni ali 21 dni v celotnem času zdravljenja.
- 10. Tekoča farmacevtska formulacija za uporabo po zahtevku 8, kjer se anti-humano PD-1 protitelo ali njegov antigen vezavni fragment daje v odmerku 5,0 mg/kg ali 10 mg/kg, ki se daje v intervalih vsake 2 tedna ali vsake 3 tedne v teku zdravljenja.
- 11. Tekoča farmacevtska formulacija za uporabo po zahtevku 8, kjer je terapija zdravljenje melanoma, pri čemer se anti-humano PD-1 protitelo ali njegov antigen vezavni fragment daje v odmerku 3,0 mg/kg, ki se daje v intervalih vsake 3 tedne v teku zdravljenja.
- 12. Tekoča farmacevtska formulacija za uporabo po zahtevku 8, ki se daje v 30-minutni IV infuziji.
- 13. Tekoča farmacevtska formulacija za uporabo po katerem koli od zahtevkov 8-12, kjer je zdravljenje naivnega subjekta.
- 14. Tekoča farmacevtska formulacija za uporabo po katerem koli od zahtevkov 8-12, kjer je zdravljenje subjekta, ki je bil predhodno zdravljen z dodatnimi kemoterapevtiki.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161470121P | 2011-03-31 | 2011-03-31 | |
EP12763896.3A EP2691112B1 (en) | 2011-03-31 | 2012-03-29 | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
PCT/US2012/031063 WO2012135408A1 (en) | 2011-03-31 | 2012-03-29 | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2691112T1 true SI2691112T1 (sl) | 2018-07-31 |
Family
ID=46931903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201231319T SI2691112T1 (sl) | 2011-03-31 | 2012-03-29 | Stabilne formulacije protiteles za humani programiran smrtni receptor pd-1 in sorodna zdravljenja |
Country Status (22)
Country | Link |
---|---|
US (1) | US9220776B2 (sl) |
EP (2) | EP2691112B1 (sl) |
JP (1) | JP6014116B2 (sl) |
KR (4) | KR20190116563A (sl) |
CN (2) | CN107854439A (sl) |
AU (1) | AU2012236479B2 (sl) |
CA (1) | CA2830806C (sl) |
CY (1) | CY1120359T1 (sl) |
DK (1) | DK2691112T3 (sl) |
ES (1) | ES2676205T3 (sl) |
HK (1) | HK1256245A1 (sl) |
HR (1) | HRP20181139T1 (sl) |
HU (1) | HUE039209T2 (sl) |
LT (1) | LT2691112T (sl) |
MX (1) | MX341076B (sl) |
PL (1) | PL2691112T3 (sl) |
PT (1) | PT2691112T (sl) |
RS (1) | RS57492B1 (sl) |
RU (2) | RU2633509C2 (sl) |
SI (1) | SI2691112T1 (sl) |
TR (1) | TR201810298T4 (sl) |
WO (1) | WO2012135408A1 (sl) |
Families Citing this family (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0812913B8 (pt) * | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
ES2593027T3 (es) | 2009-03-30 | 2016-12-05 | Eisai R&D Management Co., Ltd. | Composición liposomal |
KR20190116563A (ko) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
NZ751452A (en) * | 2013-03-13 | 2020-04-24 | Genentech Inc | Antibody formulations |
AU2014250940A1 (en) | 2013-04-09 | 2015-10-22 | Boston Biomedical, Inc. | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer |
DK2992017T3 (da) | 2013-05-02 | 2021-01-25 | Anaptysbio Inc | Antistoffer rettet mod programmeret død-1 (pd-1) |
KR20240107197A (ko) | 2013-08-08 | 2024-07-08 | 싸이튠 파마 | 병용 약학 조성물 |
AU2014304931B2 (en) | 2013-08-08 | 2018-05-10 | Assistance Publique - Hopitaux De Paris | IL-15 and IL-15Raplha sushi domain based modulokines |
CA2920113A1 (en) * | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
CA2924172C (en) * | 2013-09-13 | 2020-06-30 | Beigene, Ltd. | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and cancer drugs |
CA2932765A1 (en) | 2013-12-05 | 2015-06-11 | Rfemb Holdings, Llc | Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb) |
WO2015085847A1 (zh) | 2013-12-12 | 2015-06-18 | 上海恒瑞医药有限公司 | Pd-1抗体、其抗原结合片段及其医药用途 |
US20160304969A1 (en) | 2013-12-17 | 2016-10-20 | Merck Sharp & Dohme Corp. | Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
US10106607B2 (en) | 2013-12-20 | 2018-10-23 | Intervet Inc. | Caninized antibodies |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
TR201901507T4 (tr) * | 2014-02-04 | 2019-02-21 | Merck Sharp & Dohme | Kanseri tedavi etmeye yönelik bir pd-1 antagonsitinin ve bir vegfr inhibitörünün kombinasyonu. |
EP3102237B1 (en) * | 2014-02-04 | 2020-12-02 | Incyte Corporation | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
EP3116542A2 (en) | 2014-03-12 | 2017-01-18 | Yeda Research and Development Co., Ltd. | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
JP6526189B2 (ja) | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | 抗pd−l1抗体並びにその治療及び診断のための使用 |
WO2016011357A1 (en) * | 2014-07-18 | 2016-01-21 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
JP6986965B2 (ja) | 2014-07-22 | 2021-12-22 | アポロミクス インコーポレイテッド | 抗pd−1抗体 |
NZ728749A (en) | 2014-08-05 | 2023-06-30 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
CA2957258C (en) | 2014-08-05 | 2023-11-07 | MabQuest SA | Immunological reagents |
WO2016032927A1 (en) | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
KR20170057339A (ko) | 2014-09-15 | 2017-05-24 | 제넨테크, 인크. | 항체 제형 |
GB201419084D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-PD-1 antibodies |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
MX2017007535A (es) | 2014-12-09 | 2017-08-10 | Merck Sharp & Dohme | Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1). |
GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
CA2975123A1 (en) | 2015-01-30 | 2016-08-04 | Rfemb Holdings, Llc | Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue |
AR103726A1 (es) * | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
EP3265122B1 (en) | 2015-03-04 | 2022-05-04 | Merck Sharp & Dohme Corp. | Combination of pembrolizumab and eribulin for treating triple-negative breast cancer |
KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
AU2016249395B2 (en) | 2015-04-17 | 2022-04-07 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-PD-1 antibody and another antibody |
EP3839510A3 (en) | 2015-04-17 | 2021-08-25 | Merck Sharp & Dohme Corp. | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
WO2016177913A1 (en) * | 2015-05-07 | 2016-11-10 | Novimmune Sa | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers |
EP3302501B1 (en) | 2015-05-29 | 2021-09-22 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer |
CA2988126A1 (en) | 2015-06-03 | 2016-12-08 | Boston Biomedical, Inc. | Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
TW201709929A (zh) | 2015-06-12 | 2017-03-16 | 宏觀基因股份有限公司 | 治療癌症的聯合療法 |
WO2016204193A1 (ja) | 2015-06-16 | 2016-12-22 | 株式会社PRISM Pharma | 抗がん剤 |
AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
EP3868406A1 (en) | 2015-06-24 | 2021-08-25 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
SG10201913303XA (en) | 2015-07-13 | 2020-03-30 | Cytomx Therapeutics Inc | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
CN106699888B (zh) * | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
CN106390115A (zh) * | 2015-07-29 | 2017-02-15 | 上海君实生物医药科技股份有限公司 | 一种人源化单克隆抗体的稳定制剂 |
SG10202010506TA (en) | 2015-07-30 | 2020-11-27 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
WO2017024465A1 (en) * | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
CN106480023B (zh) * | 2015-08-27 | 2020-07-10 | 杨光华 | 干涉片段及其应用 |
CN106480022B (zh) * | 2015-08-27 | 2020-07-10 | 杨光华 | 干涉片段及其应用 |
KR20220131277A (ko) | 2015-09-01 | 2022-09-27 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
JP6949009B2 (ja) | 2015-09-21 | 2021-10-13 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | ヒトプログラム死リガンド2(pd−l2)に結合する抗体およびその用途 |
CN106999591B (zh) * | 2015-09-28 | 2021-02-23 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体制剂及其在医药上的应用 |
US10428145B2 (en) | 2015-09-29 | 2019-10-01 | Celgene Corporation | PD-1 binding proteins and methods of use thereof |
CA3000564A1 (en) | 2015-10-02 | 2017-04-06 | Symphogen A/S | Anti-pd-1 antibodies and compositions |
US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
MA45429A (fr) | 2015-10-08 | 2019-05-01 | Macrogenics Inc | Polythérapie pour le traitement du cancer |
CN108697791B (zh) | 2015-11-03 | 2022-08-23 | 詹森生物科技公司 | 特异性结合pd-1的抗体及其用途 |
PE20181400A1 (es) * | 2015-12-07 | 2018-09-07 | Merck Patent Gmbh | Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab |
AU2016370376B2 (en) | 2015-12-14 | 2023-12-14 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
EP3394099A4 (en) * | 2015-12-22 | 2019-11-27 | Merck Sharp & Dohme Corp. | Formulations of Manipulated Anti- IL-10 Antibodies |
KR20180108655A (ko) | 2016-01-15 | 2018-10-04 | 알에프이엠비 홀딩스, 엘엘씨 | 암의 면역학적 치료 |
US11214617B2 (en) | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
EP3405497A2 (en) | 2016-01-22 | 2018-11-28 | Mabquest SA | Immunological reagents |
CN109312347A (zh) | 2016-02-19 | 2019-02-05 | 希望之城 | 双特异性适配子 |
ES2952680T3 (es) | 2016-04-28 | 2023-11-03 | Eisai R&D Man Co Ltd | Eribulina para inhibir el crecimiento tumoral |
GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
CN116903741A (zh) | 2016-06-20 | 2023-10-20 | 科马布有限公司 | 特异性结合于pd-l1的抗体或其抗原结合片段及其用途 |
AU2017293423B2 (en) | 2016-07-05 | 2023-05-25 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
WO2018018018A1 (en) * | 2016-07-21 | 2018-01-25 | Berg Llc | Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators |
WO2018027524A1 (en) | 2016-08-09 | 2018-02-15 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibody formulation |
WO2018033135A1 (en) | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
CN106977602B (zh) * | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
EP3515944A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING IMMUNE DISORDERS WITH PD-1 BINDING PROTEINS |
US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
BR112019007145A2 (pt) | 2016-10-14 | 2019-07-02 | Eisai R&D Man Co Ltd | combinação de um antagonista de pd-1 e eribulina para o tratamento de câncer urotelial |
AU2017354070A1 (en) | 2016-11-01 | 2019-05-16 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (PD-1) |
JP7178999B2 (ja) | 2016-11-18 | 2022-11-28 | シムフォゲン・アクティーゼルスカブ | 抗pd-1抗体および組成物 |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
JP7106563B2 (ja) | 2016-11-29 | 2022-07-26 | スミトモ ファーマ オンコロジー, インコーポレイテッド | ナフトフラン誘導体、その調製、および使用方法 |
MA50948A (fr) | 2016-12-07 | 2020-10-14 | Agenus Inc | Anticorps et procédés d'utilisation de ceux-ci |
WO2018112360A1 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating cancer |
WO2018112364A1 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating melanoma |
CA3047508A1 (en) | 2016-12-23 | 2018-06-28 | Virttu Biologics Limited | Treatment of cancer |
PL3565844T3 (pl) | 2017-01-09 | 2023-06-12 | Tesaro Inc. | Sposoby leczenia nowotworów złośliwych przeciwciałami anty-pd-1 |
CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
MA47612A (fr) | 2017-02-24 | 2020-01-01 | Macrogenics Inc | Molécules de liaison bispécifiques capables de se lier à cd137 et à des antigènes tumoraux, et leurs utilisations |
WO2018162446A1 (en) * | 2017-03-06 | 2018-09-13 | Merck Patent Gmbh | Aqueous anti-pd-l1 antibody formulation |
US11939380B2 (en) | 2017-04-05 | 2024-03-26 | Les Laboratoires Servier | Combination therapies targeting PD-1, TIM-3, and LAG-3 |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
AR111432A1 (es) | 2017-04-28 | 2019-07-10 | Merck Sharp & Dohme | Biomarcadores para agentes terapéuticos contra el cáncer |
JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
CA3061050A1 (en) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
SG11201909955XA (en) | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
WO2018213297A1 (en) * | 2017-05-16 | 2018-11-22 | Bristol-Myers Squibb Company | Treatment of cancer with anti-gitr agonist antibodies |
CN110198739B (zh) | 2017-05-16 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 一种pd-l1抗体药物组合物及其用途 |
WO2018213424A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
ES2965352T3 (es) | 2017-05-30 | 2024-04-12 | Bristol Myers Squibb Co | Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3) |
US11597768B2 (en) | 2017-06-26 | 2023-03-07 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
CA3074565A1 (en) * | 2017-09-05 | 2019-03-14 | Merck Sharp & Dohme Corp. | Compounds for reducing the viscosity of biological formulations |
JP2021501150A (ja) | 2017-10-27 | 2021-01-14 | メルク・シャープ・エンド・ドーム・コーポレイション | 肝臓がんを治療するための組成物及び方法 |
EP3705134A4 (en) * | 2017-11-02 | 2021-07-28 | Nanjing Shunxin Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING A HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-L1 |
WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
KR20200120641A (ko) | 2018-01-15 | 2020-10-21 | 난징 레전드 바이오테크 씨오., 엘티디. | Pd-1에 대한 단일-도메인 항체 및 이의 변이체 |
RU2020129827A (ru) | 2018-02-13 | 2022-03-14 | Мерк Шарп И Доум Корп. | Способы лечения злокачественного новообразования с использованием антител против pd-1 |
WO2019185792A1 (en) | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
CA3111066A1 (en) | 2018-09-13 | 2020-03-19 | Merck Sharp & Dohme Corp. | Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with non-microsatellite instability-high or proficient mismatch repair colorectal cancer |
EP3876990A4 (en) * | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
EP3876978A4 (en) * | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE |
US20220107320A1 (en) | 2019-02-15 | 2022-04-07 | Incelldx, Inc. | Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein |
PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
WO2020183133A1 (en) | 2019-03-08 | 2020-09-17 | Oxford Genetics Limited | Method of selecting for antibodies |
GB201903233D0 (en) | 2019-03-08 | 2019-04-24 | Oxford Genetics Ltd | Method of selecting for antibodies |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
JP2022537324A (ja) | 2019-06-18 | 2022-08-25 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | B型肝炎ウイルス(hbv)ワクチンおよび抗pd-1抗体の組合せ |
MA56523A (fr) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1 ou anti-pd-l1 |
US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
TW202135860A (zh) * | 2019-12-10 | 2021-10-01 | 美商再生元醫藥公司 | 含有抗cd20x抗cd3雙特異性抗體之穩定調配物 |
WO2021123202A1 (en) | 2019-12-20 | 2021-06-24 | Formycon Ag | Formulations of anti-pd1 antibodies |
TW202130367A (zh) * | 2020-01-15 | 2021-08-16 | 大陸商信達生物製藥(蘇州)有限公司 | 結合pd-1和pd-l1的雙特異性抗體的製劑及其用途 |
JP2023511080A (ja) * | 2020-01-24 | 2023-03-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 安定な抗体製剤 |
CN113456582B (zh) * | 2020-03-30 | 2024-06-14 | 鲁南制药集团股份有限公司 | 重组人源化抗pd-1单克隆抗体的液体制剂 |
WO2022003554A1 (en) | 2020-07-01 | 2022-01-06 | Pfizer Inc. | Biomarkers for pd-1 axis binding antagonist therapy |
WO2022049526A1 (en) | 2020-09-02 | 2022-03-10 | Pharmabcine Inc. | Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer |
CN115315509B (zh) * | 2021-02-08 | 2024-05-07 | 苏州沙砾生物科技有限公司 | 肿瘤浸润淋巴细胞的制备方法及其用途 |
WO2022256483A1 (en) | 2021-06-03 | 2022-12-08 | Surface Oncology, Inc. | Methods of treating cancer with an anti-cd39 antibody and pembrolizumab |
GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
WO2022268887A1 (en) | 2021-06-23 | 2022-12-29 | Formycon Ag | Formulations of anti-pd1 antibodies |
TW202328438A (zh) | 2021-12-08 | 2023-07-16 | 新加坡商泰莎治療有限公司 | 淋巴瘤之治療 |
WO2023198115A1 (en) * | 2022-04-14 | 2023-10-19 | Beigene Switzerland Gmbh | Stable high concentration sodium chloride formulations containing pd-1 antibody and methods of use thereof |
WO2024133625A1 (en) | 2022-12-21 | 2024-06-27 | Formycon Ag | Formulations of anti-pd1 antibodies |
WO2024160721A1 (en) | 2023-01-30 | 2024-08-08 | Kymab Limited | Antibodies |
WO2024171082A1 (en) | 2023-02-16 | 2024-08-22 | Sun Pharmaceutical Industries Limited | Stable protein compositions of anti-pd1 antibody |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
ZA966075B (en) * | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
RU2497500C2 (ru) | 1995-07-27 | 2013-11-10 | Джинентех, Инк | Стабильная изотоническая лиофилизированная протеиновая композиция |
EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
PL198123B1 (pl) | 1999-02-22 | 2008-05-30 | Baxter Int | Kompozycja czynnika VIII bez dodatku albuminy i jej zastosowanie |
JP4317010B2 (ja) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
US20070134247A9 (en) | 2002-04-12 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
EP2270051B1 (en) | 2003-01-23 | 2019-05-15 | Ono Pharmaceutical Co., Ltd. | Antibody specific for human PD-1 and CD3 |
SK50672005A3 (sk) | 2003-02-10 | 2006-03-02 | Elan Pharmaceuticals, Inc. | Prípravok imunoglobulínu a spôsob jeho prípravy |
US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
WO2005117967A2 (en) | 2004-04-12 | 2005-12-15 | Medimmune, Inc. | Anti-il-9 antibody formulations and uses thereof |
US20110142858A1 (en) | 2004-06-07 | 2011-06-16 | Ramot At Tel Aviv University Ltd. | Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
MX2007009091A (es) | 2005-01-28 | 2008-01-11 | Wyeth Corp | Formulaciones de polipeptido liquidas estabilizadas. |
CA3151350A1 (en) * | 2005-05-09 | 2006-11-16 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
AU2006278573A1 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
KR20080098504A (ko) | 2006-02-03 | 2008-11-10 | 메디뮨 엘엘씨 | 단백질 제제 |
EP1998806A1 (en) | 2006-03-28 | 2008-12-10 | F. Hoffmann-Roche AG | Anti-igf-1r human monoclonal antibody formulation |
CL2008000058A1 (es) | 2007-01-09 | 2008-05-23 | Wyeth Corp | Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden. |
WO2008100562A2 (en) | 2007-02-14 | 2008-08-21 | Medical College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
BRPI0812913B8 (pt) | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
US20100286038A1 (en) | 2007-09-21 | 2010-11-11 | Valentyn Antochshuk | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
WO2009120684A1 (en) | 2008-03-25 | 2009-10-01 | Medimmune, Llc | Antibody formulation |
EP2307050A4 (en) * | 2008-07-04 | 2012-07-25 | Ono Pharmaceutical Co | USE OF A EFFECTIVENESS MARKER TO OPTIMIZE THE THERAPEUTIC EFFECTIVENESS OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS |
EP2331090B1 (en) | 2008-09-19 | 2018-01-03 | Pfizer Inc. | Stable liquid antibody formulation |
RU2481824C2 (ru) * | 2008-10-29 | 2013-05-20 | Аблинкс Н.В | Препараты однодоменных антигенсвязывающих молекул |
WO2010069858A1 (en) | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
WO2010100200A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Lyophilised antibody formulation |
US20120121580A1 (en) | 2009-07-28 | 2012-05-17 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
TW201201835A (en) * | 2010-03-17 | 2012-01-16 | Abbott Res Bv | Anti-nerve growth factor (NGF) antibody compositions |
WO2012018538A2 (en) | 2010-07-26 | 2012-02-09 | Schering Corporation | Bioassays for determining pd-1 modulation |
KR20190116563A (ko) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
-
2012
- 2012-03-29 KR KR1020197029183A patent/KR20190116563A/ko active Application Filing
- 2012-03-29 ES ES12763896T patent/ES2676205T3/es active Active
- 2012-03-29 TR TR2018/10298T patent/TR201810298T4/tr unknown
- 2012-03-29 CN CN201711445710.5A patent/CN107854439A/zh active Pending
- 2012-03-29 KR KR1020217025071A patent/KR102614259B1/ko active IP Right Grant
- 2012-03-29 HU HUE12763896A patent/HUE039209T2/hu unknown
- 2012-03-29 DK DK12763896.3T patent/DK2691112T3/en active
- 2012-03-29 CA CA2830806A patent/CA2830806C/en active Active
- 2012-03-29 PL PL12763896T patent/PL2691112T3/pl unknown
- 2012-03-29 PT PT127638963T patent/PT2691112T/pt unknown
- 2012-03-29 KR KR1020217000971A patent/KR102289394B1/ko active IP Right Grant
- 2012-03-29 EP EP12763896.3A patent/EP2691112B1/en active Active
- 2012-03-29 WO PCT/US2012/031063 patent/WO2012135408A1/en active Application Filing
- 2012-03-29 RS RS20180817A patent/RS57492B1/sr unknown
- 2012-03-29 SI SI201231319T patent/SI2691112T1/sl unknown
- 2012-03-29 EP EP18173280.1A patent/EP3398612A1/en active Pending
- 2012-03-29 CN CN2012800145404A patent/CN103429264A/zh active Pending
- 2012-03-29 MX MX2013011246A patent/MX341076B/es active IP Right Grant
- 2012-03-29 US US14/008,604 patent/US9220776B2/en active Active
- 2012-03-29 LT LTEP12763896.3T patent/LT2691112T/lt unknown
- 2012-03-29 KR KR1020137028390A patent/KR102031020B1/ko active IP Right Grant
- 2012-03-29 RU RU2015123476A patent/RU2633509C2/ru active
- 2012-03-29 JP JP2014502771A patent/JP6014116B2/ja active Active
- 2012-03-29 RU RU2013148537/10A patent/RU2563346C2/ru active
- 2012-03-29 AU AU2012236479A patent/AU2012236479B2/en active Active
-
2018
- 2018-06-27 CY CY20181100660T patent/CY1120359T1/el unknown
- 2018-07-20 HR HRP20181139TT patent/HRP20181139T1/hr unknown
- 2018-11-29 HK HK18115290.5A patent/HK1256245A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2691112T1 (sl) | Stabilne formulacije protiteles za humani programiran smrtni receptor pd-1 in sorodna zdravljenja | |
EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
RU2011144312A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИ-ErbB-3/АНТИ-С-МЕТ АНТИТЕЛА | |
FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
BR112017009398A2 (pt) | moléculas de ligação específicas para cd73 e seus usos | |
CA2988604C (en) | Pharmaceutical combination and uses thereof | |
UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
NZ719036A (en) | Anti-pdl1 antibody formulations | |
RU2014138474A (ru) | Новые модуляторы и способы применения | |
CA2579861A1 (en) | Formulation of pertuzumab in a histidine-acetate buffer | |
AR111497A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos | |
BR112014006175B1 (pt) | Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile | |
JP2016515124A5 (sl) | ||
RU2015143607A (ru) | Составы антител | |
KR102104296B1 (ko) | 종양성 질병들에 대한 치료 | |
RU2015104001A (ru) | Комбинированная терапия для лечения глиобластомы | |
EP2358395A4 (en) | METHOD AND FORMULATION FOR REDUCING THE AGGREGATION OF A MACROMOLECULUM UNDER PHYSIOLOGICAL CONDITIONS | |
FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
RU2012108108A (ru) | Концентрированные полипептидные лекарственные формы с пониженной вязкостью | |
RU2014145841A (ru) | Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы | |
JP2016531123A (ja) | Il−17アンタゴニストを使用して汎発性膿疱性乾癬(gpp)を処置する方法 | |
EA201491352A1 (ru) | Способ лечения рака груди | |
WO2020123477A1 (en) | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist | |
RU2015147913A (ru) | Антитело против рецептора эпидермального фактора роста |